Gerald Miletello, MD
Basic profileMedical Oncology
Gerald Miletello is an Oncology physician. OpenAlex indexes 20 publications with 402 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
76 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202514 payments$380
- AstraZeneca Pharmaceuticals LPProgram year202516 payments$330
- Novartis Pharmaceuticals CorporationProgram year202514 payments$303
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
33.1%PD-1 inhibitor31.7%Pembrolizumab100%Part B, office-administered≥11 patientsAromatase Inhibitor0.6%Letrozole56%Anastrozole44%Part D≥39 patients+ 9 more classes in this area
Metabolism & gastrointestinal
29.4%Substance P/Neurokinin-1 Receptor Antagonist23.8%Aprepitant100%Part B, office-administered≥19 patientsSerotonin-3 Receptor Antagonist5.2%Palonosetron hcl70%Ondansetron hydrochloride26%Ondansetron Hcl3%Ondansetron Odt1%Part D + Part B≥41 patients+ 3 more classes in this area
Musculoskeletal
23.2%RANK Ligand Inhibitor23.2%Denosumab100%Part B, office-administered≥27 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A randomized trial of a multimodal lifestyle intervention in cancer survivors
Frontiers in Oncology
2025 - Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2
Journal of Investigative Medicine
2021 - Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Journal for ImmunoTherapy of Cancer
2019 - Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM2019
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”